Oxford BioDynamics' (LON:OBD) CEO, Jon Burrows joins Proactive London's Katie Pilbeam to discuss the launch of their COVID-19 Severity test in the US.
Requiring only a routine blood draw, this prognostic test is able to identify high-risk individuals who, if exposed to the SARS-CoV-2 virus, are likely to experience the most severe COVID-19 complications and will potentially require hospitalization and intensive care unit (ICU) support.